ZURICH (Reuters) – Novartis plans to spin off its Alcon eye care business to shareholders and repurchase up to $5 billion in shares, as Chief Executive Vas Narasimhan refocuses the Swiss firm on prescription drugs.
Source:: Reuters – Business News
ZURICH (Reuters) – Novartis plans to spin off its Alcon eye care business to shareholders and repurchase up to $5 billion in shares, as Chief Executive Vas Narasimhan refocuses the Swiss firm on prescription drugs.
Source:: Reuters – Business News
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.